India said to be pushing back against EU's oversight proposal on capital flows citing sovereignty concerns
capital flows
, two Indian government sources said.
The proposal, unusual in most free trade agreements, has raised concerns in New Delhi over limiting its ability to act unilaterally during crises, as both sides aim to conclude the deal by the end of 2025.
India has in the past imposed restrictions on outflows, including during a currency crisis in 2013.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
The Top 25 Most Beautiful Women In The World
Articles Vally
Undo
In its proposal to India, the EU has suggested an oversight committee on trade in services and investment policies which would review policy actions, including those taken during financial or balance of payments crises.
"India fears such oversight could allow the committee to question or reverse crisis-time policy measures taken by it, which compromises a sovereign's decision-making powers," one of the sources said.
Live Events
India, which trades $190 billion in goods annually with the EU, has also sought clarity on whether decisions taken during emergencies, such as restrictions on capital flows, could be overturned if the committee finds them inappropriate.
While trying to limit India's control over capital account decisions, the EU proposes it would have the right to impose temporary restrictions on capital outflows during serious economic difficulties.
India argues this creates an imbalance in safeguard powers and deviates from the EU's own practice in FTAs with Vietnam, Singapore, and South Korea, where both sides can apply such measures in exceptional circumstances, the source said.
Both sources declined to be identified as they are not authorised to the media.
Emails sent to the Reserve Bank of India, Ministries of Finance and Commerce and to the Prime Minister's Office requesting comment did not receive a response.
SEEKING BALANCED TRADE PACTS
India's opposition to the EU's proposal comes as it negotiates deals with other trading partners including the U.S. and Australia.
Accepting oversight or unequal safeguards could limit India's powers on domestic policies and may weaken its push for balanced trade pacts in the future, the sources said.
"India has not had an agreement on the
FTA
so far because of issues such as these...because every country in the bloc wants their point of view or interest to be included," a source from the Ministry of External Affairs said.
The European Commission, in its report following the July round of negotiations in Brussels, said "good progress" had been made on capital movements, payments, and transfers, with discussions focused on remaining areas of divergence.
India-EU trade talks have faced hurdles over the EU's push to cut import taxes on cars and dairy while seeking stricter climate and labour rules. India wants to protect local farmers, avoid rigid green rules, and keep control over legal disputes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
20 minutes ago
- New Indian Express
Trump tariff move unlikely to derail Tamil Nadu's industrial ambitions: Industries Minister Rajaa
CHENNAI: Tamil Nadu is prepared to absorb the impact of new US tariffs, State Industries Minister Dr TRB Rajaa said on Thursday, after US President Donald Trump announced a 25% duty on goods imported from India, escalating trade tensions between the two countries. Speaking on the sidelines of the second edition of Passenger Vehicle Expo, Rajaa said India's most industrialised state had already laid contingency plans to shield key sectors such as manufacturing, textiles, and footwear from sudden trade shocks. 'We've seen the Covid impact, we've seen global disruptions,' he said. 'If there's one state that's resilient enough to weather this, it's Tamil Nadu.' Rajaa said he was 'unhappy' with Trump's rhetoric. 'As an Indian, and as a representative of Tamil Nadu, I found the language disturbing. But we will stand by the Union government and hope the Prime Minister and his Cabinet respond with wisdom, balancing the interests of our farmers, the primary sector, and industry.' He also warned against overinterpreting the tariff move based on a single post. 'This is diplomacy in trade between two of the world's largest economies,' he said. 'It's unfortunate the US President chose such a platform for such a major announcement. But I trust Prime Minister Narendra Modi will respond in the appropriate format.'
The Wire
20 minutes ago
- The Wire
From ‘Howdy Modi' to ‘Cannot Name Trump': How Modi Has Taken a Hit from Trump's Tariffs and Taunts
Trump's actions hit directly at the pillars propping up Modi's domestic political strength in ways visible and hard to immediately fix. Prime Minister Modi, accompanied by US President Donald Trump, writes in the visitor's book at the White House. Photo: Press Information Bureau/GODL. New Delhi: US President Donald Trump's announcement of steep tariffs on India, his criticism of the Indian economy as "dead" and his public overtures towards Pakistan have placed Prime Minister Narendra Modi, more than India as a nation, in a uniquely difficult spot. While the impact on India as a country is tangible, it is a moment of political reckoning for Modi, who has been under pressure since the 2024 Lok Sabha elections when the BJP lost its majority in the house. Here are the reasons it places Modi in a tough spot. Destroys Modi's domestic image of a global statesman Modi has painstakingly cultivated an image of himself domestically as a top global leader exhibiting close personal friendships with the world's most influential heads of state, particularly in the US. Trump's public insults and punitive tariffs undermine this persona, making Modi appear ineffective or even powerless in protecting Indian interests and standing on the world stage. Under pressure from the US, he has already succumbed to China, even though Beijing continues to pile on pressure and refuses to make any concessions. This severely erodes Modi's political brand at home, where he and his party have used images from his foreign trips to project influence domestically. Political ammunition for domestic opposition With Trump – the first for an American president – openly criticising the Indian economy and labelling it 'dead', opposition parties such as the Congress have seized upon these remarks to portray Modi's economic approach and foreign outreach as failures. They argue that Modi's support of Trump during previous years has unravelled, leaving India diplomatically isolated and economically vulnerable. Modi's failure to name Trump in his Lok Sabha speech, despite an open challenge by leader of opposition Rahul Gandhi, has shown him as weak and scared of standing up to the US president. This provides ammunition for the opposition parties to politically target Modi when he is already being challenged by the Rashtriya Swayamsevak Sangh on the issue of the election of the new BJP president. Setbacks undermine Modi's central arguments The new US tariffs threaten to erode the competitiveness of Indian exports, damage investor sentiment and threaten to bury Modi's faltering attempts to get global manufacturing to India. Key labour-intensive sectors such as jewellery, textiles and certain electronics face certain job losses. These outcomes create immediate economic pain and threaten Modi's narrative of making India an economic powerhouse as the 'fourth-largest economy in the world'. If the US also follows through on penalties related to India's Russia policy, the fallout could be even more severe. Energy prices could rise and India's fiscal deficit could increase, putting further pressure on the budget and bringing greater distress to the people. Hyphenation with Pakistan sours nationalist dreams Trump's statements and overtures that club India with Pakistan, including praising a new US-Pakistan energy deal and openly patronising Islamabad, are a direct affront to Modi's narrative of India as a regional counterweight to both Pakistan and China. The perception that the US is tilting toward Pakistan, or using India-Pakistan tensions for leverage, is particularly damaging to Modi's core nationalist constituency, which takes pride in a strong, singular global standing for India. It believed that India cannot be equated with its neighbour or seen as needing US mediation to end the conflict. Modi's inability to secure even this basic gain of the UPA era damages his ' desh nahi jhukne doonga ' brand among his core Hindutva supporters. Loss of bargaining leverage hurts economy Modi's strategy had relied on fostering goodwill and leveraging the India-US relationship for favourable trade agreements and strategic cooperation. Trump's abrupt imposition of tariffs, at rates higher than those faced by competing Asian economies, signals that Washington is willing to use harsh tactics, regardless of personal or diplomatic ties. This despite Modi rushing to meet Trump after his re-election early this year. New Delhi is now left scrambling for a response, with very limited leverage, and must consider politically costly concessions or risk a further downturn in exports and economic growth. After 11 years of being in power, Modi can't shift the blame on anyone else and will be held accountable for the severe economic downturn in the public eye. In sum, Trump's actions and rhetoric hit directly at pillars propping Modi's domestic political strength and standing, in ways that are both visible and hard to quickly repair. The impact on India will be managed, but it is Modi, as a political leader and as an electoral brand, who now faces the greatest challenge in his eleven years in office. The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.
Hans India
20 minutes ago
- Hans India
Agilent Supports India's Global Biopharma Ambitions with State-of-the-Art Experience Center in Hyderabad
Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, today announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally. The center was inaugurated by Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. For Hyderabad's vibrant ecosystem of startups, academic institutions, and skilled professionals, the center unlocks direct access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports faster R&D, hands-on training aligned with international regulatory standards, and stronger collaboration between industry and academia. By addressing critical challenges in biosimilars, biologics, and precision medicine, the facility strengthens Hyderabad's position as a trusted global hub for next-generation drug development, and a key contributor to India's biopharma growth story. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO, Agilent Technologies. 'Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.' Located in the heart of India's life sciences capital, the center is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, 'Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.' Hyderabad offers one of the most mature and future-focused life sciences ecosystems in India, combining deep industry expertise, strong R&D capabilities, and a supportive policy environment. With its legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. The launch of the Agilent Biopharma Experience Center builds on this foundation, introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This capital investment is part of Agilent's broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent's global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent's efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. 'Agilent is already working closely with many of India's leading biopharma companies,' added McDonnell. 'With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.' This milestone marks a new chapter in Agilent's journey with India—deepening collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
